For consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals.
Find out more about NPS RADAR.
| Title | Why read this |
|---|---|
| NPS RADAR December 2006 Professional publication - NPS RADAR - Complete issue | NPS RADAR articles provide timely, independent, evidence-based assessment of new drugs, new PBS listings and research for health professionals. |
| Trastuzumab (Herceptin) PBS listed for early breast cancer Professional publication - NPS RADAR - Brief item | Trastuzumab is listed on the PBS as an authority prescription for the initial and continuing treatment of HER2-positive early breast cancer, starting concurrently with adjuvant chemotherapy after surgical excision. |
| Rosiglitazone with metformin combination tablets (Avandamet) listed on the PBS. Professional publication - NPS RADAR - Brief item | Rosiglitazone with metformin in a fixed-dose combination tablet (Avandamet) was listed on the PBS as a third-line choice, after metformin and/or a sulfonylurea. |
| Exemestane (Aromasin) and letrozole ( Femara) listings extended to early breast cancer in postmenopausal women Professional publication - NPS RADAR - Brief item | The PBS restriction for exemestane and letrozole was extended to include adjuvant treatment of hormone-dependent early breast cancer in postmenopausal women. |
| Hydroxocobalamin should be given every 2-3 months Professional publication - NPS RADAR - Brief item | The maximum quantity of hydroxocobalamin has been increased from 2 to 3 ampoules, so that it may be given every 2-3 months for prevention of vitamin B12 deficiency. |
| Erratum: Fentanyl patches (Durogesic) for chronic pain Professional publication - NPS RADAR - Brief item | Information about equi-analgesic doses of methadone have been removed from 'Table 1: Equipotency of opioid analgesics to oral morphine 30 mg', in the Dosing Issues section of this NPS RADAR review published in the August 2006 issue. |
| Amlodipine with atorvastatin (Caduet) for dyslipidaemia with concomitant hypertension or angina Professional publication - NPS RADAR - Review | Reviews use of amlodipine/atorvastatin combination for concurrent dyslipidaemia, hypertension, and angina in comparison with use as single agent therapy. |
| Imiquimod cream (Aldara) for superficial basal cell carcinoma Professional publication - NPS RADAR - Review | Reviews topical use of imiquimod for superficial basal cell carcinoma, including indications for use and comparison with other treatments. |
| Insulin glargine (Lantus) for type 1 and 2 diabetes mellitus Professional publication - NPS RADAR - Review | Reviews use of insulin glargine for diabetes mellitus, including comparison with isophane insulin and risk of hypoglycemia. |
| Pimecrolimus cream (Elidel) for facial atopic dermatitis Professional publication - NPS RADAR - Review | Reviews use of pimecrolimus cream for facial atopic dermatitis when topical corticosteroids are contraindicated. |
| Rosuvastatin (Crestor) for dyslipidaemia Professional publication - NPS RADAR - Review | Reviews use of rosuvastatin for dyslipidaemia, including target LDL-C levels, dosage guidelines, and safety profile. |
Complete list of all NPS RADAR content.
Find out more about NPS RADAR.
Date published: 2006-12-01 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.